J. Pharm. Technol. Res. Manag.

Modified Excipients in Novel Drug Delivery: Need of the Day

Neha Kanojia, Loveleen Kaur, Manju Nagpal and Rajni Bala

  • Download PDF
  • DOI Number

excipients, functionality, synthetic, stability, bioavailability

PUBLISHER The author(s) 2013. This article is published with open access at www.chitkara.edu.in/publications

Drug products not only contain “activesâ€Â that confer the intended therapeutic beneits such as pain relief or act on particular part of the body, but contain other materials that are also “functionalâ€Â with respect to the drug product. These are known as excipients and speciic functionality which they confer to a particular product is independent upon the process used to add the excipient to the formulation and its exact location within the inal dosage form. Introduction of novel drug delivery systems and new drug moieties lead to the need for new excipients with varied characteristics. Development of new excipient entities and their evaluation is a costly procedure; modiication of existing excipients is very easy, more economical and less time consuming. The development of excipients that are capable of fulilling multifunctional roles such as enhancing drug bioavailability and drug stability as well as controlling the release of the drug according to the therapeutic needs is one of the most important prerequisites for further progress in the design of novel drug delivery systems. The main focus of this article is on synthetic novel excipients that perform multiple functions in pharmaceutical formulations.

Page(s) 81–107
URL http://dspace.chitkara.edu.in/jspui/bitstream/1/50/1/11006_JPTRM_Neha%20Kanojia.pdf
ISSN Print : 2321-2217, Online : 2321-2225
DOI https://doi.org/10.15415/jptrm.2013.11006
  • Abbas, K.A.(2010). “Modified Starches and Their Usages in Selected Food Products: A reviewStudy”,J Agri Sci, Vol. 2(2), pp.90-100.
  • Bansal, A.K.and Nachaegari, S.K. (2004) “Coprocessed excipient for solid dosage form”.Pharmaceutical Technology, pp. 52-64.
  • Bharate, Sonali S., Bharate, Sandip B. and Bajaj, Amrita N. (2010) “Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review”, Journal of Excipients and FoodChemicals, Vol 1(3), pp.3-26.
  • Blecher, L. (1993) “Pharmaceutical Excipients: Producers and Users strengthen their Voice”,Pharmaceutical Technology,Vol 17(2), pp. 38–39.
  • Brewster, Marcus E. and Loftsson, Thorsteinn (2007) “Cyclodextrins as Pharmaceutical Solubilizers”, AdvancedDrug Delivery Reviews, Vol 59, pp. 645–666. https://doi.org/10.1016/j.addr.2007.05.012
  • Buckton, G. (2008) “Excipients and Delivery systems for Pharmaceutical Formulation”, Royal Society of Chemistry , Vol 34(4), pp. 373-383.
  • Chakraborty, Subhashis, Shukla, Dali, Vuddanda, Parameswara Rao, Mishra, Brahmeshwar and Singh, Sanjay (2010) “Utilization of adsorption technique in the development of oral delivery system of lipid based nanoparticles”, Colloids and Surfaces B: Biointerfaces, Vol 81, pp. 563-69. https://doi.org/10.1016/j.colsurfb.2010.07.058
  • Chang, Edward I, Galvez, Michael G, Glotzbach, Jason P, Hamou, Cynthia D, El-ftesi, Samyra, Rappleye, C Travis, Sommer, Kristin-Maria, Rajadas, Jayakumar, Abilez, Oscar J, Fuller, Gerald G, Longaker, Michael T and Gurtner, Geoffrey C (2011) “Vascular Anastomosis using controlled phase transition in polaxamer gels”,Nature Medicine, Vol 17, pp. 1147-1152. https://doi.org/10.1038/nm.2424
  • Chaudhary, P.D., Pathak, A.A. and Desai, Ujwala (2012) “A Review: Co processed Excipients-An Alternative to Novel Chemical entities”,International Journal of Pharmaceutical and Chemical Sciences , Vol 1(4), pp.1480-1498.
  • Chaudhary, Sunita A., Chaudharya, A.B. and Mehta T.A. (2010) “Excipients Updates for Orally Disintegrating Dosage Forms”, International Journal of Research in Pharmaceutical Sciences,Vol 1(2), pp.103-107.
  • Chougule, A.S., Dikpati, A. and Trimbake T. (2012) “Formulation development of coprocessed excipients”, Journal of Advanced Pharmaceutical Sciences,Vol 2(2), pp.231-249.
  • David, Stephanie, Pitard, Bruno, Benoita, Jean-Pierre and Passirania, Catherine (2010) “Non-viral Nanosystems for Systemic sIRNA Delivery”, Pharmacological Research , Vol 62, pp. 100–114. http://dx.doi.org/10.1016/j.phrs.2009.11.013
  • El-Barghouthi, Musa, Eftaiha, Ala'a, Rashid, Iyad, Al-Remawi, Mayyas and Badwan, Adnan (2008) “A novel super disintegrating agent made from physically modified chitosan with silicon dioxide”,DrugDevelopment and Industrial Pharmacy, Vol 34(4), pp. 373-83. http://dx.doi.org/10.1080/03639040701657792
  • Ender, K., Cabelka, T., Jacob, K., Denomme, D. and Wallick, D.(2007) “A New Hypromellose Excipient for Direct Compression Controlled Release Applications”,American Association of Pharmaceutical ScientistsAnnual Meeting Abstract # 002440.
  • Flores, Luis Estrada, Arellano, Raquel Lopez and Esquivel, Juan Jose Diaz (2000) “Study of load capacity of Avicel PH200 and cellactose, two direct-compression excipients using experimental design”, Drug Development and Industrial Pharmacy , Vol 26(4), pp. 465-469. https://doi.org/10.1081/DDC-100101256
  • Gohel, M.C. and Jogani, P.D. (2005) “A review of directly compressible excipients”, Journal of Pharmaceutical Sciences , Vol 8(1), pp.76-93.
  • Gordon Bardley(2012).“Surface active proteins as excipients in solid pharmaceutical formulations”. US Patent (US8226967 B2) July 24 2012.
  • Gorgegoan (2006) “Fiber rich fraction of trigonella foenum-graceum seeds and its use as a pharmaceutical excipient”. US Patent (EP1697050A2) Sep 6, 2006
  • Goyanes, Alvaro, Souto, Consuelo and Martinez-Pacheco Ramon (2011) “Co processed MCC-Eudragit E excipients for extrusion–spheronization”, European Journal of Pharmaceutics and Biopharmaceutics,Vol.79, pp. 658–663. https://doi.org/10.1016/j.ejpb.2011.07.013
  • Hapgood, Karen P., Tan, Melvin X.L. and Chow, Darren W.Y. (2009) “A method to predict nuclei size distributions for use in models of wet granulation”, Advanced Powder Technology , Vol.20, pp. 293–297. https://doi.org/10.1016/j.apt.2008.09.004
  • Huang, Ye, Khanvilkar, Kavita H., Moore, Angela D. and Hilliard-Lott, Marquetta (2003) “Effects of Manufacturing Process Variables on In vitro Dissolution Characteristics of Extended-Release Tablets formulated with Hydroxypropyl Methylcellulose”, Drug Development and Industrial Pharmacy , Vol.29(1),pp.79-88. https://doi.org/10.1081/DDC-120016686
  • Joan Cucala Escoi(2005).Modified calcium phosphate excipient.US Patent (20050031862 A1) 10,Feb, 2005.
  • Marwaha, Minakshi, Sandhu, Deepak and Marwaha, Rakesh Kumar (2010) “Co processing of excipients: a review on excipient development for improved tableting performance”, International Journal of AppliedPharmaceutics, Vol.2 (3), pp.41-47.
  • Medina,Maria de la Luz Reus, Kumar Vijay (2006) “Evaluation of cellulose II powders as a potential multifunctional excipient in tablet formulations”, International Journal of Pharmaceutics, Vol 322(2), pp.31-35. https://doi.org/10.1016/j.ijpharm.2006.05.033
  • Michael J.K. (1993) “Spray drying and spray congealing of pharmaceuticals In: Encyclopedia of pharmaceutical technology’. Marcel Dekker INC, NY, Vol 14, 207-221.
  • Michaud, J. (2002) “Starch based excipients for pharmaceutical tablets”, Pharmaceutical Chemistry,pp.42-44.
  • Manudhane Krishna S.,Contractor, Avinash M., Kim Hyo Y. and Shangraw Ralph F. (2010). “Tableting properties of a directly compressible starch”,Journal of Pharmaceutical Sciences , Vol 58(5), pp.616-620. https://doi.org/10.1002/jps.2600580524
  • Miclea, Razvan D., Purohit, Vivek S. and Balu-Iyer, Sathy V. (2007) “O-Phospho-L-Serine, Multi-functional Excipient for B Domain Deleted Recombinant Factor VIII”, The American Association of PharmaceuticalScientistsVol 9(2), pp.251-259. https://doi.org/10.1208/aapsj0902028
  • Miller, R.W. (1997) “Roller compaction technology In: Handbook of Pharmaceutical Granulation Technology”, Parikh D.M. (Ed.), Marcel Dekker. pp. 100–149.
  • Okimoto, Kazuto, Rajewski, Roger A., Uekama, Kaneto, Jona, Janan A. and Stella  Valentino J. (1996) “The interaction of charged and uncharged drugs with neutral (HP-beta-CD) and anionically charged (SBE7-beta- CD) beta-cyclodextrins”, Pharmtech Research , Vol 13(2), pp.256-264. https://doi.org/10.1023/A:1016047215907
  • Parker, A. (2009) “Focus on excipients”,Chemistry Today, Vol 27(1), pp.5-7
  • Parker, A. (2009) “SYLOID® FP Multifunctional excipients for the pharmaceutical industry”,Chemistry Today,Vol 27(5), pp. 1-2.
  • Patel, R.P., Patel, M.P. and Suthar, A.M. (2009) “Spray drying technology: an overview”, Indian Journal of Science and Technology,Vol 2(10), pp. 44-45.
  • Pawar, Smita K. and Vavia, Pradeep R. (2012) “Rice Germ Oil as Multifunctional Excipient in preparation of Self- Microemulsifying Drug Delivery System (SMEDDS) of Tacrolimus”, American Association of Pharmaceutical Scientists, Vol 13(1), pp.255-261. https://doi.org/10.1208/s12249-011-9748-1
  • Pifferi, Giorgio and Restani, Patrizia (2003) “The safety of pharmaceutical excipients”,II Farmaco,Vol 58, pp. 541-550. https://doi.org/10.1016/S0014-827X(03)00079-X
  • Prasanna, R.Y., Jayasri, V., Yasmeen, R.B., Chowdary, H.V. and Satyanandam, S. (2011) “Significance of Pharmaceutical Excipients-A Review”, Journal of Innovative trends in Pharmaceutical Sciences,Vol2(6), pp.191-201.
  • Rashid, I., Al-Remawi, M., Leharne, S.A., Chowdhry, BZ.and Badwan A. (2011) A novel multifunctional pharmaceutical excipient: Modification of the permeability of starch by processing with magnesium silicate, International Journal of Pharmaceutics, Vol 411, pp.18–26M
  • Rashid, I., Al-Remawi , M., Eftaiha, A. and Badwan A. (2008) Chitin-Silicon dioxide Co precipitate as a novel superdisintegrant, Journal of Pharmaceutical Sciences , Vol 97(11),pp.4955-4969.
  • Rashid,I., Al-Remawi, M., Eftaiha, A. and Badwan, A. (2008) Chitin-silicon dioxide co precipitate as a novel superdisintegrant, Journal of Pharmaceutical Sciences , Vol 97, pp. 4955–4969.
  • Retrieved from < URL http://www.contractpharm.com.html>
  • Retrieved from
  • Retrieved from <URLhttp://www.ich.org/LOB/media/MEDIA1957.pdf.html>
  • Retrieved from
  • Retrieved from < URL http:// www.colorcon.com>
  • Retrieved from < URL http:// www.Cydexinc.com>
  • Retrieved from < URL http:// www.Excipients.com>
  • Retrieved from < URL http:// www.galenIQ.com>
  • Retrieved from < URL http:// www.meggle-pharma.com>
  • Retrieved from < URL http:// www.Neusilin.com>
  • Retrieved from < URL http://www.SPIPharma.com>
  • Retrieved from
  • Retrieved from < www.pharma-ingredients.basf.com>
  • Retrieved from < URL http:// www.fda.gov/cder/guidance/index.htm>
  • Retrieved from < URL http://www.ipecamericas.org>
  • Retrieved from
  • Reynolds, G., Ingale, R., Roberts, R., Kothari, S., Gururajan, B. (2010) ”Practical application of roller compaction process modelling”, Computers and Chemical Engineering , Vol 34, pp.1049–1057.
  • Rohokale, S.S., Dhanorkar, YD., Pahuja, V. and Kulkarni, G.T. (2012) “Characterization of selected Polysaccharide hydrogels as pharmaceutical excipients” , Journal of Chronotherapy and Drug Delivery, 3, Vol 2, pp.41-54.
  • Romain Callaird (2011). “Modified protein excipient for delayed-release tablet”.US Patent (0076326)31MARCH.Russell, R. (2004). “Synthetic Excipients Challenge All-Natural Organics”.PharmaceuticalTechnology,Vol 28, pp. 38-50.
  • Sene, C., Dupont, A. and Crowning, D. Characterising polymeric excipients. Innovations in Pharmaceutical Technology, pp.81-91.
  • Sene, C., Neun. D, Tan-sen hee, L. and Ulman, K. (2002) “Silicones as excipients for topical pharmaceutical applications”. Dow corning internal document form Vol. 52-1034-01. Sherwood, BE. and Becker, JW. (1998). “A New Class of High Functionality Excipients: Silicified Microcrystalline Cellulose”, Pharmaceutical Technology , Vol. 22(10), pp.78-88.
  • Sheskey, PJ. and Williams, DM. (1996) “Comparison of Low-Shear and High-Shear Wet Granulation Techniques and the Influence of Percent Water Addition in the Preparation of a Controlled- Release Matrix Tablet Containing HPMC and a High-Dose, Highly Water-Soluble Drug”. Pharmaceutical Technology, vol. 20, pp. 81-92.
  • Steinberg, M., Brozelleca, J.F., Enters, E.K., Kinoshita, F.K., Loper, A., Mitchell, D.B., Tamulinas,C.B. and Weiner, M.L. (1996). “A new approach to the safety assessment of pharmaceutical excipients”, Regulatory Toxicology and Pharmacology, 24, pp.149-154
  • Steinberg, M., Blecher, L. and Mercill, A. (2001) “From Inactive Ingredients to Pharmaceutical Excipients”, Pharmaceutical Technology,Vol. 25(7), pp. 62–64.
  • Velagaleti, R. (2009). “Excipient Innovation and Regulatory Acceptance for Use in Drug Products– Solubilizer Solutol® HS 15 Case Study”. Presented at: Annual Meeting of the American Association of Pharmaceutical Scientists. Los Angeles, CA, USA, November (2009).
  • Vincent green(2006). Tablet excipient US patent (0008521 A1) JAN 2006.
  • Vuorinen, S., Heinamaki, J., Antikainen, O., Lahcini, M., Repo, T. and Yliruusi, J. (2009). “Sugar End-Capped Poly-D, L-lactides as Excipients in Oral Sustained Release Tablets”, American Association of Pharmaceutical Sciences, Vol. 10(2), pp.566-573.
  • York, F.P. and Rowe, R.C. (2000). “Process control and scale-up of pharmaceutical wet granulation processes: a review”, European Journal of Pharmaceutics and iopharmaceutics , Vol. 52, pp.269–277.
  • York, P. (1992). “Crystal Engineering and particle design for the Powder Compaction Process”,Drug Development and Industrial Pharmacy, Vol. 18(6), pp.677–721.
  • Zeleznik, J.A. and Renak, J. (2004). “High Functionality Excipients (HFE) –PROSOLV® SMCC as an Effective Strategy for Generic Drug Formulation”, Business Briefing: Pharma Generics,pp. 1-4